Journal Image
Current Cardiology Reviews
ISSN (Print): 1573-403X
ISSN (Online): 1875-6557
Epub Full Text Article
DOI: 10.2174/1574884708666131117125508      Price:  $95

A Practical Guide to the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)

Author(s): Brent N. Reed and Carla A. Sueta
This review will outline the management of patients with symptomatic systolic or heart failure with reduced ejection fraction (HFrEF), i.e., those with structural heart disease and previous or current symptoms. Determination of volume status and appropriate diuretic administration is important in heart failure management. Inhibition of the renin-angiotensin-aldosterone and sympathetic nervous systems improves survival and decreases hospitalizations in patients with systolic or reduced ejection fraction HF (HFrEF). Beta blockers and aldosterone antagonists improve ejection fraction. Indications for additional agents including nitrates plus hydralazine, digoxin, statins, omega 3 polyunsaturated fatty acids, anticoagulants, and antiarrhythmics will be discussed. Choice of agents, dose-related effects, strategies to minimize adverse effects, and medications to avoid will be presented
ACE Inhibitor, aldosterone antagonist, angiotensin receptor blocker, beta blocker, heart failure with reduced ejection fraction, systolic heart failure
University of North Carolina, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599-7075